Exelixis, Inc. (EXEL)
44.15
-2.04
(-4.42%)
USD |
NASDAQ |
Jan 08, 16:00
44.15
0.00 (0.00%)
After-Hours: 19:51
Exelixis Research and Development Expense (Annual): 910.41M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Vanda Pharmaceuticals, Inc. | 74.43M |
| ADMA Biologics, Inc. | 1.813M |
| Aldeyra Therapeutics, Inc. | 48.22M |
| Merck & Co., Inc. | 15.79B |
| Neurocrine Biosciences, Inc. | 707.60M |